AHA Recommendations for Secondary Stroke Prevention

In this episode, “AHA Recommendations for Secondary Stroke Prevention,” the panelists explore the following questions:

1. Can you discuss AHA recommendations for stroke prevention in different patient groups (transient ischemic attack [TIA], noncardioembolic ischemic stroke, etc.)?
   1. Please share, very briefly, any practice impacting updates from recently released AHA guidelines for early management of stroke.

Dual antiplatelet therapy (aspirin plus clopidogrel or ticagrelor) is now guideline‑recommended for patients with minor ischemic stroke or high‑risk TIA, typically for 21 days, because bleeding risk outweighs benefit beyond about three weeks; an exception is intracranial atherosclerotic disease, where DAPT may be extended to ~90 days. For patients with atrial fibrillation–related (cardioembolic) stroke, recent data support starting anticoagulation early—even within the first 48 hours for small to moderate infarcts. Guidelines also call for aggressive lipid lowering (e.g., statins to achieve LDL <70 mg/dL in non‑cardioembolic stroke, <100 mg/dL in cardioembolic stroke), alongside a heart‑healthy, plant‑rich diet, with emerging interest in the microbiome and environmental contributors to atherosclerosis. Finally, tight blood pressure control is critical: targets have shifted from 140/90 mmHg toward ≤130/80 mmHg (and often the 120s systolic when safe), requiring long‑term, coordinated management with primary ca

The next episode in this series, “Hypertension Management and Secondary Stroke Prevention,” features the panelists advancing their conversation on secondary stroke prevention.